PHAT logo

PHAT Phathom Pharmaceuticals, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$4.66
-0.42 (-8.27%)

Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Euro…

Market Cap: $378.82Mwww.phathompharma.com

Price

No data yet.

Social Signal Score

62
5d
62
2 mentions
—
30d
61
9 mentions
—
60d
64
12 mentions
—
90d
61
13 mentions
—
news: 13

Analyst Ratings

9 analysts
Buyconsensus
Strong Buy 0Buy 8Hold 1Sell 0Strong Sell 0
Avg price target$16.5+254.1%
Low $10Median $15.5High $22
Current Consensus

Revenue

$84.72M
$0.00$28.24M$56.48M$84.72M
Mar 2018Sep 2026

Analyst Estimates

FY2025
$-3.16
$-3.39–$-2.82
3 analysts
FY2026
$-0.83
$-0.89–$-0.74
4 analysts
FY2027
$0.61
$0.55–$0.66
4 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Steven L. Basta
Sector
Healthcare
Industry
Biotechnology
Employees
371
Beta
0.50
Country
US
Piotroski score
3 / 9 (Weak)
Altman Z-score
-4.88
www.phathompharma.com